title: Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.
abstract: The role of adjuvant ovarian suppression or ablation (OS/OA) in premenopausal women with hormone receptor-positive breast cancer remains controversial. The purpose of our study was to examine which patients might benefit from the addition of OS/OA to tamoxifen. We analyzed the data of 2065 premenopausal patients with hormone receptor-positive invasive ductal carcinomas who were treated at Sun Yat-Sen University Cancer Center from 2000 to 2008. The five-year disease-free survival rate (DFSR) and overall survival rate (OSR) were compared by menstrual status and treatment. Compared with patients older than forty years of age, patients younger than forty years old had significant lower DFSRs and OSRs. The addition of OS/OA to tamoxifen increased the DFSR and OSR of patients with normal menstrual cycles after chemotherapy, regardless of their age at diagnosis. Patients with normal menstrual cycles after chemotherapy are the main beneficiaries of an adjuvant OS/OA.
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Cong
authors: C
authors: Xue
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Roujun
authors: R
authors: Peng
authors: Department of GCP, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Ye
authors: Y
authors: Cao
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Shusen
authors: S
authors: Wang
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Yanxia
authors: Y
authors: Shi
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Xin
authors: X
authors: An
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Fei
authors: F
authors: Xu
authors: Department of medical oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative innovation center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, People's Republic of China.
authors: Zhongyu
authors: Z
authors: Yuan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008598:Menstruation; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010052:Ovariectomy; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D017697:Premenopause; D012189:Retrospective Studies; D013629:Tamoxifen / Q000737:chemistry / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone